September 2008- Volume 4, Issue 9

In this Issue

Genomics & Proteomics

Focus on the gene scene

Focus on the gene scene

Broad Institute releases free Integrative Genomics Viewer

‘Zoom lens’ for sequencing

‘Zoom lens’ for sequencing

TGen and febit collaborate to refine new DNA capture method

Follow the leader

Follow the leader

Alnylam arranges licenses to gain dominant IP position in RNAa

Rosetta, NIH to ID microRNA drug targets

Rosetta, NIH to ID microRNA drug targets

In a collaboration that aims to find potential drug targets for treating human immunodeficiency virus (HIV) infection, Rosetta Genomics—which has headquarters both in Israel and Jersey City, N.J.—will work with the National Institutes of Health (NIH) to identify microRNAs implicated in HIV viral replication and their function.

Of mice and HIV models

Of mice and HIV models

Researchers come up with a more humanized HIV mouse model

Feature

Take a really good look

Take a really good look

Mining data may be the easy part; visualizing it for proper analysis and development is the big challenge now

Research & Development

Venturing into vaccines

Venturing into vaccines

Sanofi Pasteur to buy vaccine supplier Acambis

Clear kidney connection

Clear kidney connection

Cytochroma, Mitsubishi Tanabe ink deal for chronic kidney disease therapeutics

What’s old is new again

What’s old is new again

PhytoMedical to develop Dartmouth’s forgotten cancer compounds

Making their mark

Making their mark

Biomarker company Clinical Data acquires Adenosine Therapeutics

Changing the R&D landscape

Changing the R&D landscape

Lilly sells Greenfield Labs, signs 10-year, $1.6 billion R&D deal with Covance

Automation & Instrumentation

Fluorescent tags for live cells

Fluorescent tags for live cells

Promega, Leica set sights on sub 100 nm live cell imaging

Caliper extends screening services

Caliper extends screening services

Adds RapidKinase profiling and enzymatic mechanism of action studies

Multi-mode partnership

Multi-mode partnership

BioTek and fledgling assay company Gyrasol sign co-marketing agreement

Custom-made deal

Custom-made deal

Invitrogen, Lentigen to provide custom lentiviral gene-overexpression products

Editor's Focus

Few bargains in biotech acquisitions

Few bargains in biotech acquisitions

A funny thing happened on the way to the biotech bargain basement the big companies had been picking over, the pharmas and biotechs on display like so many shirts on a clearance rack at Nordstrom’s: the acquisition targets started saying, “No, we don’t want your funny billion dollars, we’re worth more.”

Commentary

At what cost (overzealous) reactions?

At what cost (overzealous) reactions?

Franklin Roosevelt suggested that “the only thing we have to fear is fear itself.” There are many other things to fear, and one of them is poorly reported medical data.

Pharma faces Congressional battles in 2009

Pharma faces Congressional battles in 2009

Industry sees little difference in proposed policies of Obama and McCain

Informatics

Breaking down clinical barriers

Breaking down clinical barriers

Pharsight, CRI Worldwide team up to improve clinical trial efficiency

A sum greater than its parts

A sum greater than its parts

SDI combines forces with Verispan to create comprehensive healthcare industry database

Clinic-to-research connection

Clinic-to-research connection

Sealy Center, GenoLogics to develop biomedical informatics solution

A broader protein vision

A broader protein vision

Waters teams with Proteome Software for protein visualization

The power of Pattern Array

The power of Pattern Array

University of Maryland researchers see commercial opportunity for novel data mining software

Global News

Alpharma: ‘No thanks’ to $1.4 billion offer

Alpharma: ‘No thanks’ to $1.4 billion offer

King Pharmaceuticals makes unsolicited $33 per share bid for specialty pharma company

Back in the game

Back in the game

PDL BioPharma inks deal with Bristol-Myers Squibb for multiple myeloma candidate elotuzumab

Valeant, Meda strike multiple deals

Valeant, Meda strike multiple deals

Valeant sells Western, Eastern Europe operations to Meda for $392 million

ImClone says no to BMS

ImClone says no to BMS

Oncology biopharma rejects BMS' $4.5B acquisition offer
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022